Pain Relief Shouldn't Begin With Pain
SYNERA® is a prescription pain patch that combines lidocaine, tetracaine, and heat to provide local dermal analgesia for superficial venous access and superficial dermatological procedures.1
Applied to the site of the procedure, it provides effective local pain relief to the skin in as little as 20 minutes!1, 2
If you are a healthcare professional who would like to learn more about SYNERA®, click here.
If you are a patient who would like to learn more about SYNERA®, click here.
References: 1. SYNERA® complete prescribing information. 2. Sawyer J, et al. Heated lidocaine/tetracaine patch (Synera™, Rapydan™) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. BR J Anaesth 2009; 102:210-215. 3. Masud S, et al. J Pain Symp Manage 2010; 40:510-519. 4. Data on File. 5. Wallace MS et al. Evaluation of the depth and duration of anesthesia from heated lidocaine/tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med 2010; 35:507-513. 6. Curry SE, Finkel JC. Use of the Synera™ patch for local anesthesia before vascular access procedures: a randomized, double-blind, placebo-controlled study. Pain Med. 2007 Sep; 8(6):497-502. 7. Sethna NF, Verghese ST, Hannallah RS, Solodiuk JC, Zurakowski D, Berde CB. A randomized controlled trial to evaluate S-Caine patch for reducing pain associated with vascular access in children. Anesthesiology. 2005 Feb; 102(2): 403-408. 8. Berman B, Flores J, Pariser D, Pariser R, de Araujo T, Ramirez CC. Self-warming lidocaine/tetracaine patch effectively and safely induces local anesthesia during minor dermatologic procedures. Dermatol Surg. 2005 Feb; 31(2):135-138. 9. Hession PM, Joshi GP. Sedation not quite that simple. Anesthesiology Clin. 2010:281-294.
Important Safety Information For SYNERA® (70 mg lidocaine/70 mg tetracaine)
SYNERA® topical patch is indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures.
SYNERA® is contraindicated in patients with a known history of sensitivity to lidocaine, tetracaine, local anesthetics of the amide or ester type, or any other component of the product and in patients with para-aminobenzoic acid (PABA) hypersensitivity. Keeping a patch on longer than recommended or applying multiple patches simultaneously or sequentially could result in systemic absorption sufficient to result in serious adverse effects that are typical of drugs in this class.
Even a used SYNERA® patch contains a large amount of lidocaine and tetracaine (at least 90% of the initial amount). Chewing or ingesting a new or used SYNERA® patch may result in serious adverse effects. Store and dispose of SYNERA® out of the reach of children and pets.
SYNERA® should be used with caution in patients who may be more sensitive to the systemic effects of lidocaine and tetracaine, including the acutely ill, the debilitated, and those with compromised hepatic function. Patients with severe hepatic disease or pseudocholinesterase deficiency are at greater risk of developing toxic plasma concentrations.
Allergic or anaphylactoid reactions (urticaria, angioedema, bronchospasm, and shock) to the active or inactive components of SYNERA® can occur and should be managed by conventional means.
Avoid contact of SYNERA® with the eyes due to potential irritation or abrasion. If contact occurs, immediately wash out the eye with water or saline, and protect it until sensation returns.
Safety and effectiveness of SYNERA® have been established in patients 3 years or older.
Lidocaine has been shown to inhibit viral and bacterial growth. The effect of SYNERA® on intradermal injections of live vaccines has not been determined.
The heating component contains iron powder, and the patch must be removed before magnetic resonance imaging.
SYNERA® may lead to diminished or blocked sensation in the treated skin; therefore, patients should avoid inadvertent trauma (rubbing, scratching, or exposure to heat or cold) before complete sensation returns.
SYNERA® should be used with caution in patients receiving class 1 antiarrhythmics and/or other local anesthetics, because the systemic toxic effects may be additive and potentially synergistic with lidocaine and tetracaine.
In clinical studies, the most common local reactions were erythema (71%), blanching (12%), and edema (12%); these reactions were generally mild, resolving spontaneously soon after treatment.
Do not cut or remove the top cover of the patch as this could result in thermal injury.
SYNERA® is not for home use by patient.
Please see complete Prescribing Information before using SYNERA®.